DEVELOPMENT OF A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL FOR VENLAFAXINE AND O-DESME THY LVENLA FAXINE: ASSESSING THE IMPACT OF CYP2D6, CYP2C9 AND CYP2C19 GENETIC POLYMORPHISMS

被引：0
|
作者：
Pan, X. [1 ]
Rowland-Yeo, K. [1 ]
机构：
[1] Certara UK, Simcyp Div, Edinburgh, Scotland
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-167
引用
收藏
页码：S103 / S104
页数：2
相关论文
共 50 条
  • [21] Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese
    He, Li
    Chen, Shaojun
    Li, Jingao
    Xie, Xiaoxue
    Huang, Lihua
    Kuang, Yun
    Xu, Kangwei
    Huang, Wanxia
    Zhao, Yanling
    Yang, Guoping
    Guo, Chengxian
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2020, 47 (10) : 1659 - 1663
  • [22] Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects
    Sijie Lu
    R. A. Nand
    J. S. Yang
    Gang Chen
    A. S. Gross
    European Journal of Clinical Pharmacology, 2018, 74 : 285 - 296
  • [23] Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19
    Park, Hye-Jung
    Lee, Sang-Ho
    Kang, Pureum
    Cho, Chang-Keun
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    Bae, Jung-Woo
    Choi, Chang-Ik
    ARCHIVES OF PHARMACAL RESEARCH, 2025, : 234 - 250
  • [24] Impact of Genetic Polymorphisms in CYP2C9 and CYP2C19 on the Pharmacokinetics of Clinically Used Drugs
    Hirota, Takeshi
    Eguchi, Shunsuke
    Ieiri, Ichiro
    DRUG METABOLISM AND PHARMACOKINETICS, 2013, 28 (01) : 28 - 37
  • [25] The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population
    T. Fukuda
    Y. Nishida
    Q. Zhou
    I. Yamamoto
    S. Kondo
    J. Azuma
    European Journal of Clinical Pharmacology, 2000, 56 : 175 - 180
  • [26] The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population
    Fukuda, T
    Nishida, Y
    Zhou, Q
    Yamamoto, I
    Kondo, S
    Azuma, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (02) : 175 - 180
  • [27] Genetic Polymorphisms of NAT2, CYP2C9, CYP2C19, CYP2D6 and CYP2E1, and Antituberculosis Drugs Induced Maculopapular Eruption
    Kim, S.
    Kim, S.
    Moon, J.
    Kim, T.
    Sohn, J.
    Yoon, H.
    Shin, D.
    Park, S.
    Jee, Y.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) : AB357 - AB357
  • [28] Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity Role of CYP2D6 and CYP2C19 in longevityRole of CYP2D6 and CYP2C19 in longevity
    L. Bathum
    K. Andersen-Ranberg
    J. Boldsen
    K. Brøsen
    B. Jeune
    European Journal of Clinical Pharmacology, 1998, 54 : 427 - 430
  • [29] Efficiency to detect PM of CYP2D6, CYP2C9, and CYP2C19 based on volunteers' phenotype and genotype.
    Masson, E
    Tassé, C
    Larouche, R
    Girard, B
    LeBel, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P40 - P40
  • [30] Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population
    Krasniqi, Valon
    Dimovski, Aleksandar
    Bytyqi, Hasime Qorraj
    Eftimov, Aleksandar
    Simicevic, Livija
    Bozina, Nada
    ARHIV ZA HIGIJENU RADA I TOKSIKOLOGIJU-ARCHIVES OF INDUSTRIAL HYGIENE AND TOXICOLOGY, 2017, 68 (03): : 180 - 184
12345